Literature DB >> 26152833

Bone-anchored hearing implants in single-sided deafness patients: Long-term use and satisfaction by gender.

Hubert T Faber1, Rik C Nelissen1, Sophia E Kramer2, Cor W R J Cremers1, Ad F M Snik1, Myrthe K S Hol1.   

Abstract

OBJECTIVES/HYPOTHESIS: To examine the long-term satisfaction and possible effects of gender in patients with single-sided deafness (SSD) who underwent bone-anchored hearing implant (BAHI) surgery. STUDY
DESIGN: Retrospective case-control study.
METHODS: All (n = 145) consecutive SSD patients fitted with a BAHI between January 2001 and October 2011 were asked to complete a questionnaire consisting of the Abbreviated Profile of Hearing Aid Benefit (APHAB), the Communication Profile for the Hearing Impaired (CPHI), and the SSD questionnaire.
RESULTS: Twenty-three of the 135 responding patients (17%) reported discontinuation of the device over an average follow-up time of 61.7 months. No significant differences were found in the degree of disability or coping between men and women, according to the APHAB and CPHI scores. Improvement in quality of life and appreciation of the BAHI were not affected by gender, age, directional hearing ability, and handling of the device. The appearance of the device positively affected their appreciation. At the mean follow-up time of 117 months, 69.2% was using their BAHI. In the domains background noise, reverberant surroundings, and aversion to sounds, the mean APHAB scores were significantly changed at 3 months, 1 year, and 10 years after implantation.
CONCLUSION: Our study examined the results of BAHI use in SSD patients over a relatively long follow-up period, with an average of 5 years. The majority of users (83%) were satisfied with the device. No significant gender differences were in terms of reported appreciation, hearing disability, or coping with a BAHI. LEVEL OF EVIDENCE: 3b.
© 2015 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  APHAB; BAHI; Bone anchored hearing implant; CPHI; SSD; gender; hearing loss; long-term results; satisfaction; single-sided deafness

Mesh:

Year:  2015        PMID: 26152833     DOI: 10.1002/lary.25423

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Evaluation of wireless Bluetooth devices to improve recognition of speech and sentences when using a mobile phone in bone conduction device recipients.

Authors:  Tae Hoon Kong; Chanbeom Kwak; Woojae Han; Young Joon Seo
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-06-19       Impact factor: 2.503

2.  Use of a 3D reconstruction model in a patient with severe atresia auris for optimal placement of Bonebridge transcutaneous bone conduction implant.

Authors:  Antonio Della Volpe; Antonietta De Lucia; Valentina Ippolito; Vincenzo Pastore; Luigi Iuppariello; Mario Formisano; Fabrizio Clemente; Arianna Di Stadio
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-03       Impact factor: 2.503

3.  Rerouting Hearing Aid Systems for Overcoming Simulated Unilateral Hearing in Dynamic Listening Situations.

Authors:  Erin M Picou; Dawna Lewis; Gina Angley; Anne Marie Tharpe
Journal:  Ear Hear       Date:  2020 Jul/Aug       Impact factor: 3.570

4.  Hearing-Related Quality of Life in 75 Patients With a Percutaneous Bone Conduction Device.

Authors:  Coosje Jacoba Isabella Caspers; Rik Chrétien Nelissen; Hans J M M Groenewoud; Myrthe Karianne Sophie Hol
Journal:  Otol Neurotol       Date:  2022-03-01       Impact factor: 2.311

5.  Minimally Invasive Ponto Surgery compared to the linear incision technique without soft tissue reduction for bone conduction hearing implants: study protocol for a randomized controlled trial.

Authors:  Tim G A Calon; Marc van Hoof; Herbert van den Berge; Arthur J G de Bruijn; Joost van Tongeren; Janny R Hof; Jan Wouter Brunings; Sofia Jonhede; Lucien J C Anteunis; Miranda Janssen; Manuela A Joore; Marcus Holmberg; Martin L Johansson; Robert J Stokroos
Journal:  Trials       Date:  2016-11-09       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.